Glenmark Pharmaceuticals Limited announced that its 48th Annual General Meeting will be held on Friday, September 11, 2026. The meeting is scheduled for 2:00 pm and will be conducted through Video Conferencing or Other Audio-Visual Means.

The company issued a public notice regarding the AGM pursuant to the Companies Act, 2013, General Circular No. 03/2025 dated September 22, 2025, issued by the Ministry of Corporate Affairs, and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The notice was published in the English daily Financial Express and the Marathi daily Loksatta – All Editions, on Saturday, August 15, 2026. The document was submitted to the National Stock Exchange of India Limited and BSE Limited by Rashmi Khandelwal, Company Secretary & Compliance Officer.

Glenmark Pharmaceuticals has entered into a settlement agreement with Humana, Inc. for $15.28 million ($15,285,369) to resolve a subset of consolidated antitrust and consumer protection lawsuits pending in the Eastern District of Pennsylvania, U.S. The settlement, disclosed on August 11, 2026, covers claims related to allegations of price-fixing, market allocation, and anti-competitive conduct involving generic pharmaceutical products. The company emphasized that the settlement does not constitute an admission of liability or wrongdoing, as Glenmark USA has consistently denied the allegations.

The dispute stems from more than 35 complaints filed since 2016 against Glenmark Pharmaceuticals Inc., USA ("Glenmark USA") and other generic drug manufacturers. The plaintiffs, which include direct purchasers, end-payers, indirect purchasers, private litigants, and 46 state attorneys general, alleged both drug-specific conspiracies and an overarching conspiracy among manufacturers. Three specific complaints filed by Humana were part of this consolidated litigation. Glenmark USA and other defendants have vigorously defended these matters, maintaining their denial of all allegations throughout the legal proceedings.

Under the terms of the agreement, the total settlement amount of $15.28 million, including interest, will be paid in two installments. The company stated that the full amount of the payments under the settlement agreements has already been provided for in its financials. Consequently, management indicated that this resolution will not have a significant impact on the company's overall financial position. This disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

Settlement Details

What the Numbers Show

The key analytical takeaway from this filing is the absence of immediate cash flow impact on Glenmark Pharmaceuticals' balance sheet. By confirming that the full $15.28 million provision was already recorded in prior financial statements, the company signals that this is a non-cash accounting adjustment rather than a new expense hit. This suggests that the management had previously assessed the litigation risk as probable and quantifiable, aligning the settlement outcome with earlier conservative estimates. For investors, this implies that the earnings per share for the current period will not face a sudden downward revision due to this specific legal closure, isolating the operational performance from legacy legal liabilities.